Avidity Biosciences (RNA) Expected to Announce Earnings on Thursday

Avidity Biosciences (NASDAQ:RNA) is expected to be issuing its Q3 2026 resultson Thursday, November 12th. Analysts expect Avidity Biosciences to post earnings of ($0.8109) per share and revenue of $15.00 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Avidity Biosciences (NASDAQ:RNA) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($1.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.24. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $0.67 million. On average, analysts expect Avidity Biosciences to post ($4.45) EPS for the current fiscal year and ($6.69) EPS for the next fiscal year.

Avidity Biosciences Price Performance

Shares of RNA stock opened at $8.68 on Thursday. The company has a market capitalization of $148.51 million and a P/E ratio of -4.04. The company’s 50-day simple moving average is $9.47 and its two-hundred day simple moving average is $20.51. Avidity Biosciences has a one year low of $7.49 and a one year high of $16.77.

Analyst Ratings Changes

A number of analysts recently issued reports on RNA shares. Roth Capital initiated coverage on Avidity Biosciences in a report on Thursday, October 22nd. They issued a “buy” rating and a $15.00 price target for the company. Weiss Ratings upgraded Avidity Biosciences from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. Finally, HC Wainwright reduced their price objective on Avidity Biosciences from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.80.

About Avidity Biosciences

Avidity Biosciences, Inc is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s approach is designed to address conditions that are difficult to treat with conventional oligonucleotide therapies, including diseases affecting skeletal muscle.

Avidity’s proprietary AOC (antibody oligonucleotide conjugate) platform combines monoclonal antibodies with oligonucleotide-based medicines. The antibody component is intended to help deliver the therapeutic payload to specific tissues, while the oligonucleotide component is designed to modify or regulate disease-related RNA.